BioSpace News Archive

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced Jerome Bettis, NFL Pro Football Hall of Famer and 2006 Super Bowl champion, will serve as a Company brand ambassador.

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal clinical trial for the SurVeil™ drug-coated balloon (DCB).

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts from the Phase 3 PREVENT study of SOLIRIS® (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD) have been accepted for presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm, September 11 to 13, 2019.

The ranks of Medicare Advantage (MA) Plans are growing not only in number, but also in sophistication, observes Patrick Phillips, CEO of Cavulus, a leading technology firm that serves the MA industry

Pallium Canada welcomes the release of Health Canada’s Action Plan on Palliative Care: Building on the Framework on Palliative Care in Canada.

Scientists at the University of Birmingham have created an antimicrobial coating for steel surfaces which has proven to rapidly kill bacteria that cause some of the most common hospital-acquired infections.

EcoGen Laboratories, the leading vertically-integrated manufacturer and supplier of hemp-derived specialty ingredients in the United States, announced the advancement of their proprietary extraction equipment responsible for the company’s strategy behind advancing their supply chain.

The long-standing partnership will introduce a new international fellowship program offering scientists around the globe opportunities to conduct groundbreaking cancer research

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that nationally and internationally renowned clinician and oncologist, Dr. Manuel Hidalgo, has confirmed that he will be Principal Investigator (PI) for PharmaCyte’s planned clinical trial

Study was joint effort of the National Kidney Foundation, the U.S. Food and Drug Administration and the European Medicines Agency